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Abstract
Vaccination has been among the greatest contributors to the past century’s dramatic improvements in health and life expectancy.
Recent advances in vaccinology have resulted in new vaccines that will likely lead to substantial future health gains. However, the high
cost of these new vaccines, such as the human papillomavirus (HPV) vaccine, poses an obstacle to their widespread adoption in many
countries. Economic evaluation can help to determine if investment in vaccine introduction is worthwhile. However, existing economic
evaluations usually focus on a narrow set of vaccination-mediated benefits—most notably avoided medical-care costs—and fail to
account for several categories of potentially important gains. We consider three sources of such benefit and discuss them with respect
to HPV vaccination: (i) outcome-related productivity gains, (ii) behaviour-related productivity gains, and (iii) externalities. We also high-
light that HPV vaccination protects against more than just cervical cancer and that these other health gains should be taken into
account. Failing to account for these broader benefits of HPV vaccination could result in substantial underestimation of the value of
HPV vaccination, thereby leading to ill-founded decisions regarding its introduction into national immunization programmes.
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Introduction
Vaccination has been among the greatest contributors to the
past century’s dramatic improvements in health and life
expectancy. The start of the World Health Organization’s
(WHO) Expanded Programme on Immunization (EPI) in
1974 played a key role in this success. The EPI aimed to
improve worldwide vaccination coverage [1,2] and estab-
lished standard immunization policies and schedules that
helped to guide national immunization programmes world-
wide [3]. The original EPI schedule contained six vaccines,
including diphtheria–tetanus–pertussis vaccine, measles-con-
taining vaccine, polio vaccine and bacillus Calmette–Gue´rin
vaccine. Some countries have since updated their EPI sched-
ules to include vaccines that protect against Haemophilus in-
fluenzae type b, yellow fever, hepatitis B and other infectious
diseases.
In recent years, a number of new vaccines such as the
pneumococcal conjugate vaccine and the human papillomavi-
rus (HPV) vaccine have come onto the market. Compared
with the original EPI vaccines, these new vaccines are more
costly, partly as the result of their complex, patent-protected
technologies, such as recombination techniques, carrier pro-
teins and adjuvants [4,5]. In addition, recent analyses suggest
that increased regulatory oversight is another factor driving
up the price of new vaccines [6,7]. As Table 1[8,9] shows,
the per-dose prices of pneumococcal conjugate and HPV
vaccines are each more than five times that of diphtheria–
tetanus–pertussis.
For today’s policymakers facing tight healthcare budget
constraints, economic evaluation could help to determine
whether new vaccines should be added to national immuni-
zation programmes [10]. Indeed, national policymakers and
international organizations commonly use the results of eco-
nomic evaluation to inform spending decisions on vaccination
programmes:
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• The United States’ Advisory Committee on Immunization
Practices (ACIP) offers guidance on vaccine adoption and
delivery. Its governing charter states that ‘when consider-
ing recommendations for use of a vaccine, ACIP members’
deliberations should include consideration of vaccine effi-
cacy as well as cost:benefit and risk:benefit analyses’ [11].
• The United Kingdom’s National Institute for Health and
Clinical Excellence is charged with supporting healthcare-
related decisions, including vaccine introduction status,
through economic evaluation [12].
• The GAVI Alliance, the international public–private part-
nership charged with ‘[s]aving children’s lives and protect-
ing people’s health by increasing immunization in poor
countries’ [13], uses economic evaluation to inform spend-
ing and project-planning activities [14,15].
There are different approaches to economic evaluation and
it is essential to understand—both conceptually and in prac-
tice—the scope and properties of each, because these could
affect results and their interpretation [16]. In this paper, we
discuss two important aspects of economic evaluation of vac-
cination: the breadth and the measurement of the benefits
that are accounted for in the analysis. We first introduce a
general framework to account for a full range of vaccination
benefits. We then apply the general framework to HPV vac-
cination to argue that economic evaluation of HPV vaccina-
tion should include a far broader set of vaccination benefits
than is currently standard practice.
Broadening the Scope of Benefits in
Evaluating Vaccines
Existing economic evaluations of vaccination usually adopt a
narrow perspective that incorporates benefits closely linked
to the healthcare sector, such as health gains and averted
medical spending. Broader vaccination benefits are usually
overlooked in these analyses [16,17]. This is a potentially sig-
nificant oversight insofar as recent studies show that popula-
tion health affects economic development through a number
of pathways. For example, healthier people tend to be physi-
cally stronger and so able to work longer and harder
[18,19]. Healthier children and young adults are more likely
to attend and progress through school [20–22]. Higher levels
of education imply higher economic productivity because
education improves people’s ability to execute complex tasks
effectively and efficiently. In addition, in populations with
lower child mortality and longer life expectancy, families tend
to have fewer children and invest more in each child’s educa-
tion, in turn boosting economic productivity when these chil-
dren enter the labour market [23]. Finally, a healthy
workforce also attracts foreign direct investment, which can
be used to expand physical capital and infrastructure and
introduce technology that enhances economic productivity
[24].
How might we structure our thinking on both health and
economic benefits in economic evaluations of vaccination?
We would suggest a framework that takes a broad perspec-
tive and captures benefits that are commonly considered as
well as benefits that are commonly neglected in economic
evaluations of vaccination (Table 2). The latter category of
benefits includes:
• Outcome-related productivity gains. These can result
because many of the diseases that vaccinations prevent
can lead to long-term physical, mental or cognitive
changes, including paralysis, deafness or blindness [25].
Insofar as vaccine-preventable diseases can cause physical
disability, impair cognitive development and reduce school
attendance, they can result in decreased educational attain-
ment and adult earnings [26–28].
• Behaviour-related productivity gains. These can result
because many of the diseases that vaccinations prevent
can lead to behaviours affecting productivity. For example,
with increased child survival as a result of avoiding vac-
cine-preventable disease, a typical family will be able to
achieve its desired number of children through fewer
births [29–31]. Raising fewer children allows parents to
invest more resources in each child, including spending
that improves health and educational outcomes—and it
enables more women to enter the labour force [31–34].
• Externalities. These include vaccination-related herd
effects—whereby unvaccinated members of a community
incur protection from disease through the vaccination of
others [35,36]—and reductions in the development of
drug resistance because vaccination prevents cases of a
disease that are typically treated (and mistreated) with
drugs to which pathogens can develop resistance [16].
TABLE 1. New vaccines are priced higher than original
Expanded Programme on Immunization vaccines: US vac-
cine prices for 2012a
Year of
licensure Price per dose
DTP vaccine Mid-1940s US$ 20.96
Pneumo vaccine 2000 US$ 120.95
HPV vaccine 2006 US$ 130.27 (quadrivalent)
US$ 128.75 (bivalent)
DTP, diphtheria-tetanus-pertussis (acellular pertussis vaccine); Pneumo, pneumo-
coccal conjugate; HPV, human papillomavirus. Source: [8,9].
aPrices refer to the private sector price per dose, as reported by manufacturers
to the US Centres for Disease Control and Prevention.
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Given the framework laid out in Table 2, benefit–cost analy-
sis is a more natural approach to economic evaluation than
cost-effectiveness analysis, even though the latter is more
commonly used. Unlike cost-effectiveness analysis, which val-
ues a single health outcome in natural or composite units
(e.g. averted cases or disability-adjusted life-years, respec-
tively), benefit–cost analysis can incorporate multiple out-
comes, and those outcomes can be both health-rooted and
economically rooted because each is ultimately expressed in
monetary units (note: cost-effectiveness analysis sometimes
takes account of the economic benefits of an intervention by
using them to offset costs). Using monetary units is useful
not just for setting spending priorities within the health bud-
get, but also for determining resource allocation across bud-
get categories: by expressing health interventions in
monetary terms, they can be compared with interventions in
other budget categories (such as education) to rank them
with respect to their return on investment.
Insofar as most existing economic evaluations of vaccina-
tion focus predominantly on the ‘narrow’ set of benefits
identified in Table 2, it is possible that economists have sig-
nificantly undervalued vaccinations—which may have resulted
in ill-founded policy decisions regarding vaccine adoption.
This possibility should encourage researchers to rework eco-
nomic evaluations of vaccination, ensuring that all relevant
benefits are taken into account. Revised results on the value
of particular vaccinations could lead policymakers to revisit
vaccination-related funding decisions.
Applying the Broadened Framework:
Examples
Is there evidence to support the assertion that economic
evaluations of vaccination should be expanded beyond just
‘narrow’ benefits and costs?
A recent study examined the literature to identify which
types of benefits and costs had been captured in existing
benefit–cost analyses of Haemophilus influenzae type b vacci-
nation [16]. None of the 11 articles reviewed accounted for
behaviour-related productivity gains and only one article con-
sidered outcome-related productivity gains and externalities,
even though it seems highly plausible that these benefits
could be substantial [16].
The following studies by researchers at the Harvard
School of Public Health empirically examined the magnitudes
of broader benefits of childhood vaccinations.
One set of studies used data from Matlab, Bangladesh to
examine the impact of vaccination on school attainment. An
analysis exploring the impact of maternal tetanus vaccination
on schooling outcomes in children showed that there were
significant schooling gains among children whose mothers
had been vaccinated relative to children whose mothers had
not been vaccinated [27]. Another analysis showed that age-
appropriate measles vaccination as a child increased the
probability of school enrolment by 9.5% among boys; no
such impact was seen for girls [38].
Another study evaluated a preliminary GAVI vaccination
programme that aimed to extend the use of new and unde-
rused childhood vaccines to 75 low-income countries during
2005–20 [39]. This study accounted for productivity-related
effects of vaccinations resulting from improvements in health
and estimated the return on investment in the GAVI immuni-
zation programme to be 12% by 2005, rising to 18% by
2020. These estimates were conservative, however, insofar
as they accounted for outcome-related productivity gains
only, and did not take other categories of benefit into
account.
Yet another study used data from the Cebu Longitudinal
Health and Nutrition Survey in the Philippines to examine
the impact of traditional EPI vaccines on cognitive gains, as
measured by language, mathematics and intelligence test
scores [26,39]. Using international evidence to translate test
score gains into earnings gains as adults, an early version of
the paper cited in [26] estimated the return on investment
in vaccination spending to be 21% [40]. This result was
TABLE 2. Economic evaluations of vaccination should take a broad perspective
Perspective Benefit categories Definition
Narrow
Broad
Health gains Reduction in morbidity and mortality through vaccination
Healthcare cost savings Savings of medical expenditures because vaccination prevents illness episodes
Care-related productivity gains Savings of patient’s and caretaker’s productive time because vaccination avoids the need for care
Outcome-related productivity gains Increased productivity because vaccination improves physical or mental health
Behaviour-related productivity gains Vaccination improves health and survival, and thereby changes individual behaviour, for example by
lowering fertility or increasing investment in education
Externalities Improved outcomes in unvaccinated community members, e.g. through herd effects and reduction
in the pace at which resistance to antibiotics develops
This framework is based on [37] and [16].
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conservative in that it reflected only a few of the possible
benefits of vaccination—cognitive gains and a subset of
outcome-related productivity gains—and did not capture
other categories of benefit.
In both the GAVI and Cebu studies, the estimated returns
on investment in vaccination programmes compared favour-
ably with estimated returns on investment in primary educa-
tion [41], which is commonly considered to be one of the
most potent instruments of economic development [42].
Applying the Broadened Framework to
Human Papillomavirus Vaccination
Human papillomavirus (HPV) is a sexually transmitted virus
affecting both women and men [43]. Oncogenic (‘high-risk’)
types can cause various cancers. Non-oncogenic (‘low-risk’)
types are responsible for genital warts and, rarely, recurrent
respiratory papillomatosis (Fig. 1). In 2006, two vaccines that
protect against HPV entered the market: Cervarix, a biva-
lent vaccine that protects against HPV types 16 and 18; and
Gardasil, a quadrivalent vaccine that protects against types
6, 11, 16 and 18. The vaccines were initially licensed for the
prevention of HPV type 16/18-related cervical pre-cancers
and cancer only [8]; in addition, Gardasil was also licensed
for the prevention of HPV type 6/11-related genital warts.
Since then, Gardasil has also been licensed for protection
against HPV type 16/18-related anal, vaginal and vulvar pre-
cancers and cancers [44,45].
Although c.80% of all HPV-related cancer cases occur in
the developing world (Table 3) [37,43,46,47], few countries
have introduced the HPV vaccine into national immunization
programmes, owing, at least in part, to the relatively high
price of the vaccine [48]; see Table 1.
Deepening our understanding of the benefits of HPV vac-
cination would require attention to several key categories of
benefit in the conceptual framework.
First, an economic evaluation of HPV vaccination should
account for benefit categories that are typically neglected in
economic evaluations, such as outcome-related productivity
gains. Patients with HPV-related cancers must sometimes
withdraw from the workforce temporarily or permanently,
resulting in lost productivity and income. For example, in
countries like the Congo, age-specific incidence and mortality
owing to cervical cancer are greatest at ages when the
majority of women are economically active (Fig. 2). This sug-
gests that withdrawal from the workforce could hurt pro-
ductivity at both the household and national levels. For anal
Infection with oncogenic
types: 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58,
59, & 66
• Cervical cancer
• Anal cancer
• External genitalia cancer
• Oropharyngeal cancer
• Oral cancer
Infection with non-
oncogenic types:
6 &11 
• Genital warts
• Recurrent respiratory
papillomatosis
HPV 
• Family of DNA viruses
• More than 100 types
• Prevalent worldwide
FIG. 1. Taxonomy of human papilloma-
virus (HPV) infection. Source: [43].
TABLE 3. Developing countries
carry the brunt of human papillo-
mavirus (HPV) -related cancers:
global data for 2002a
Site of
cancer
Attributable
to HPV (%)
Developed countries Developing countries
Total no.
of cancers
Attributable
to HPV
Total no.
of cancers
Attributable
to HPV
Cervixb 100 83 400 83 400 409 400 409 400
Anusc 90 14 500 13 100 15 900 14 300
Penisc 40 5200 2100 21 100 8400
Vulva, vaginac 40 18 300 7300 21 700 8700
Oral/mouth ‡3 91 200 2700 183 100 5500
Oropharynx ‡12 24 400 2900 27 700 3300
Total 80 237 000 111 500 678 900 449 600
aMore recent data on overall cancer incidence is available from the International Agency for Research on Cancer’s
GLOBOCAN 2008 database. However, GLOBOCAN 2008 does not present incidence figures for all the specific
HPV-related cancer sites as they are presented in this table.
bThe quadrivalent HPV types 6/11/16/18 and the bivalent types 16/18 vaccines are currently licensed to protect
against this type of cancer.
cThe quadrivalent HPV types 6/11/16/18 vaccine is currently licensed to protect against these types of cancers.
Source [43,47].
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cancer, 2003 data from the USA show that men and women
experience 21.8 and 19.97 years of productive life lost,
respectively, for each anal-cancer-related death [49]. The lost
productivity associated with these deaths was valued at
US$ 580 292 and US$ 333 246 per case, respectively. Eco-
nomic evaluations of HPV vaccination must therefore
account for averted lost income that might otherwise result
from HPV-related disease.
Second, given that many HPV-related cancers strike during
late adulthood, an economic evaluation of HPV vaccination
should account for behaviour-related productivity gains. For
example, household-level behaviour changes such as reduc-
tions in daily food consumption were reported by patients
receiving treatment for cervical cancer in Argentina [52]. In
addition, a portion of these households reported a variety of
education-related impacts, including school absences and dif-
ficulty paying for school. Studies show that health and educa-
tional losses as a child tend to diminish productivity and
earnings as an adult. Although it is possible that the behavio-
ural effects could be negative as well, for example if HPV
vaccination increases high-risk behaviour, this has not been
reported in settings where the HPV vaccine has been intro-
duced [53,54].
Third, the framework should account for externalities,
including herd effects [35]. Given the sexually transmitted
nature of HPV, herd effects could theoretically be realized in
two ways: by vaccinating both males and females, who would
confer protection directly to their unvaccinated sexual part-
ners; or by vaccinating just females, which would reduce
transmission to their unvaccinated male partners, which
would then reduce transmission to their subsequent, unvac-
cinated female partners [55], and so on. Whereas mathemat-
ical models have predicted the impact of herd effects from
HPV vaccination [56], recent data from Australia suggest a
44% decline in the incidence of male genital warts as a result
of female HPV vaccination [57]. This finding confirms that
there could be significant herd effects resulting from HPV
vaccination. Acknowledging that the health and economic
benefits of HPV vaccination could extend to unvaccinated
members of the population should encourage researchers to
account for these gains in economic evaluation.
Finally, the framework must account for all economically
meaningful clinical endpoints (not to mention side-effects,
which should also be taken into account). Whereas many
vaccines target a single endpoint, HPV vaccination can pro-
tect against multiple endpoints (see Fig. 1). Many existing
economic evaluations of HPV vaccination focus solely on
averted cases of cervical cancer [48,58,59], and so are likely
to underestimate the true value of vaccination. For example,
data from the USA show that while cervical cancer is the
most costly HPV-related cancer to treat (US$ 146.4 million
annually; see Table 4), the costs to treat other HPV-related
cancers, which are usually ignored in economic evaluation,
are substantial. Anal cancer, of which roughly 90% is caused
by HPV (Table 3), is estimated to cost US$ 65.5 million to
treat per year. Treating vaginal and vulvar cancers, of which
roughly 40% is caused by HPV, costs c. US$ 30 million annu-
ally [46,60]. While the percentages and exact types of HPV
responsible for each clinical endpoint may vary by country,
these data suggest that failing to include clinical endpoints
beyond just cervical cancer will result in substantial underes-
timates of the value of HPV vaccination.
Conclusion
Previous economic evaluations of relatively new vaccinations
have largely focused on a ‘narrow’ set of benefit categories
[61–64]—a practice that has probably led to substantial
underestimates of the value of vaccination. Future studies
and economic evaluations of HPV vaccination should adopt a
perspective that includes outcome-related productivity gains,
behaviour-related productivity gains and externalities. In
addition, the new perspective should be applied to a com-
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FIG. 2. Cervical cancer hits women during economically productive
years: cervical cancer incidence and economic activity by age, 2008
and 2010, respectively, Congo. Source: [50,51].
TABLE 4. HPV-related diseases pose a high fiscal cost: economic burden of HPV-related disease in the USA in 2008
Cervical cancer Anal cancer Oropharynx cancer Penile cancer Vaginal cancer Vulvar cancer
US$ (millions) 146.4 65.5 153.1 4.5 7.9 20.8
Source: [60].
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prehensive set of clinical endpoints. In addition to broader
benefits, any comprehensive economic evaluation must also
account for related costs, including systems and non-systems
components, which have been discussed elsewhere [16].
Moreover, some economic evaluations may value vaccination
against alternative strategies; in the case of HPV vaccination,
for example, economists may look at the benefits and costs
of a vaccination programme relative to maintaining or
strengthening an existing cervical cancer screening pro-
gramme. Given that many countries are struggling to finance
the inclusion of HPV vaccine into national immunization pro-
grammes, such economic evaluations are urgently needed to
ensure that policymakers have information that is sufficiently
accurate and relevant to reach well-founded decisions.
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